{"id":"NCT00457392","sponsor":"Pfizer","briefTitle":"A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone","officialTitle":"A Multicenter, Randomized, Double-Blind, Controlled Phase 3, Efficacy And Safety Study Of Sunitinib (SU011248) In Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Treated With Erlotinib","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2010-07","completion":"2012-12","firstPosted":"2007-04-06","resultsPosted":"2011-08-02","lastUpdate":"2013-10-29"},"enrollment":960,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Non-Small Cell Lung"],"interventions":[{"type":"DRUG","name":"erlotinib","otherNames":[]},{"type":"DRUG","name":"sunitinib","otherNames":[]},{"type":"DRUG","name":"erlotinib","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Baseline to death or 28 days after last dose for the last participant","effectByArm":[{"arm":"Sunitinib + Erlotinib","deltaMin":9,"sd":null},{"arm":"Erlotinib","deltaMin":8.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1933"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":204,"countries":["United States","Argentina","Austria","Belgium","Brazil","Canada","Chile","Colombia","Czechia","Denmark","Germany","Greece","Hong Kong","Hungary","Italy","Netherlands","Norway","Poland","Russia","Slovakia","South Korea","Spain","Switzerland","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6181087&StudyName=A%20Study%20In%20Patients%20With%20Non-Small%20Cell%20Lung%20Cancer%20To%20Test%20If%20Erlotinib%20Plus%20SU011248%20Is%20Better%20Than%20Erlotinib%20Alone"]},"adverseEventsSummary":{"seriousAny":{"events":207,"n":473},"commonTop":["Rash","Diarrhoea","Decreased appetite","Fatigue","Nausea"]}}